drugset / Trial / NCT04669002
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
EP0057-201 is a Phase 2A/B adaptive design study. Phase 2A will test EP0057 in combination with Olaparib and Phase 2B, the randomised part of the study, will test EP0057 in combination with Olaparib against SOC chemotherapy. When EP0057 is combined with Olaparib, it is envisaged that the combination should improve therapeutic responses in the recurrent ovarian cancer disease setting. EP0057 is an investigational nanoparticle-drug conjugate administered intravenously. The rationale for developing EP0057 is to enable selective entry of EP0057 into tumour tissue and as a result create preferential accumulation of EP0057, and therefore of the payload Camptothecin, to translate into maximum tumour cell killing.
Timeline
- Start
- 2020-12-14
- Primary completion
- 2023-02-17
- Completion
- 2023-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EP0057 | Other / unclassified | — | Intravenous |
| Subject | Olaparib | Small molecule | — | — |